[go: up one dir, main page]

MX2018015474A - Metodos para el diagnostico y el tratamiento del cancer metastasico. - Google Patents

Metodos para el diagnostico y el tratamiento del cancer metastasico.

Info

Publication number
MX2018015474A
MX2018015474A MX2018015474A MX2018015474A MX2018015474A MX 2018015474 A MX2018015474 A MX 2018015474A MX 2018015474 A MX2018015474 A MX 2018015474A MX 2018015474 A MX2018015474 A MX 2018015474A MX 2018015474 A MX2018015474 A MX 2018015474A
Authority
MX
Mexico
Prior art keywords
methods
metastatic cancer
diagnosis
treatment
mirna
Prior art date
Application number
MX2018015474A
Other languages
English (en)
Inventor
Lewis John
Stoletov Konstantin
WILLETTS Lian
Original Assignee
Entos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entos Pharmaceuticals Inc filed Critical Entos Pharmaceuticals Inc
Publication of MX2018015474A publication Critical patent/MX2018015474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

Se describen los métodos para diagnosticar y tratar el cáncer metastásico en un sujeto. Los métodos implican detectar o modular la expresión de al menos uno de Kif3b, ACTB, SRPK1, TMEM229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, ARNmi 130b, ARNmi 374b o ARNmi 122 en una muestra biológica del sujeto.
MX2018015474A 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico. MX2018015474A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer
PCT/CA2017/050729 WO2017214726A1 (en) 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer

Publications (1)

Publication Number Publication Date
MX2018015474A true MX2018015474A (es) 2019-06-06

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015474A MX2018015474A (es) 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico.
MX2022012073A MX2022012073A (es) 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012073A MX2022012073A (es) 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Country Status (8)

Country Link
US (2) US11236331B2 (es)
EP (1) EP3468564A4 (es)
JP (2) JP7306829B2 (es)
CN (1) CN109562121A (es)
AU (2) AU2017285726B2 (es)
CA (2) CA2932910A1 (es)
MX (2) MX2018015474A (es)
WO (1) WO2017214726A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147822A2 (en) * 2018-01-24 2019-08-01 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
KR101446626B1 (ko) 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2014151465A1 (en) 2013-03-15 2014-09-25 Board Of Regents, The University Of Texas System Brain-specific gene signature of tumor cells
JP6663149B2 (ja) 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Also Published As

Publication number Publication date
EP3468564A1 (en) 2019-04-17
AU2023203737B2 (en) 2024-08-29
US20190177727A1 (en) 2019-06-13
JP2019525903A (ja) 2019-09-12
CN109562121A (zh) 2019-04-02
CA2932910A1 (en) 2017-12-14
JP2023123748A (ja) 2023-09-05
WO2017214726A1 (en) 2017-12-21
JP7306829B2 (ja) 2023-07-11
US12421514B2 (en) 2025-09-23
AU2023203737A1 (en) 2023-07-06
EP3468564A4 (en) 2020-07-29
AU2017285726B2 (en) 2023-03-16
AU2017285726A1 (en) 2019-01-24
US20220112498A1 (en) 2022-04-14
US11236331B2 (en) 2022-02-01
CA3027430A1 (en) 2017-12-21
MX2022012073A (es) 2022-10-18

Similar Documents

Publication Publication Date Title
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
MX2018001351A (es) Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
EA201790504A1 (ru) Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение
MX2019003035A (es) Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
MX2017006609A (es) Aditivo de nanocristales de celulosa o nanofibrillas de celulosa modificadas de forma quimica.
EP3341697C0 (en) DEVICE FOR COLLECTING, TRANSFERRING AND STORING SAMPLES OF BIOLOGICAL AND/OR CHEMICAL MATERIAL
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
BR112014026440A8 (pt) análises, métodos e aparelhos para avaliação de disrupção de rna.
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
MX2018015474A (es) Metodos para el diagnostico y el tratamiento del cancer metastasico.
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
FR3032808B1 (fr) Endoscope
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
BR112019007365A2 (pt) métodos e composições para imunoterapia com tusc2
WO2018026969A3 (en) Plazomicin antibodies and methods of use